Payment overview · 2025
General Payments
$1,240.60
67 reported records · 22 companies
Healthcare provider profile · identity verified
Phillip W Johnson, MD
Allopathic & Osteopathic Physicians|Family Medicine · LITCHFIELD, IL · NPI 1225089683
Verified facts
What the public records show
CMS Open Payments records show Phillip W Johnson, MD received $1,240.60 in general payments during 2025 across 67 reported records.
PFIZER INC. accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Caplyta, Eliquis, Ingrezza, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGLYZA as an associated drug or biological on 111 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Onglyza by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 168 claims for Trulicity by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 499 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $180.43 | 14.5% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.35 | 11.2% | 9 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $135.29 | 10.9% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $104.92 | 8.5% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $74.64 | 6.0% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $72.76 | 5.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.85 | 5.2% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $63.07 | 5.1% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $44.98 | 3.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.63 | 3.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $38.54 | 3.1% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $38.30 | 3.1% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $37.56 | 3.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.86 | 2.5% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.33 | 2.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$23.11 | 1.9% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $22.05 | 1.8% | 2 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $21.25 | 1.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.43 | 1.6% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.41 | 1.6% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $19.37 | 1.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.47 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,202.06 | 66 |
| Education | $38.54 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $143.46 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $140.80 | 9 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $135.29 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $79.74 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.25 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $74.64 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $74.64 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $72.76 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.85 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $63.07 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.28 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.99 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $47.18 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $42.63 | 2 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $38.30 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $37.56 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $33.51 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $30.86 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $29.33 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.33 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $27.55 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $22.05 | 2 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $21.25 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.43 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $19.41 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $19.37 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 499 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 86 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 115 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 16 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | ONGLYZA open payments reported associated product |
CMS Open Payments — General Payments 111 supporting records · 89 recipient NPIs · example record 1206133840 |
Onglyza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
217 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
30 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
84 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
217 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
86 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
168 | 32 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
84 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 21 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
499 | 62 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1203 | 267 |
| Levothyroxine Sodium | Levothyroxine Sodium | 729 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 619 | 142 |
| Lisinopril | Lisinopril | 535 | 118 |
| Potassium Chloride | Potassium Chloride | 526 | 82 |
| Furosemide | Furosemide | 521 | 105 |
| Eliquis | Apixaban | 499 | 62 |
| Losartan Potassium | Losartan Potassium | 455 | 96 |
| Gabapentin | Gabapentin | 449 | 83 |
| Metformin Hcl | Metformin Hcl | 431 | 93 |
| Sertraline Hcl | Sertraline Hcl | 415 | 68 |
| Omeprazole | Omeprazole | 384 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 366 | 78 |
| Metoprolol Succinate | Metoprolol Succinate | 334 | 83 |
| Trazodone Hcl | Trazodone Hcl | 332 | 63 |
| Irbesartan | Irbesartan | 271 | 68 |
| Escitalopram Oxalate | Escitalopram Oxalate | 261 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 250 | 33 |
| Carvedilol | Carvedilol | 228 | 59 |
| Tamsulosin Hcl | Tamsulosin Hcl | 228 | 49 |
| Warfarin Sodium | Warfarin Sodium | 222 | 21 |
| Jardiance | Empagliflozin | 217 | 28 |
| Tramadol Hcl | Tramadol Hcl | 212 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 208 | 47 |
| Finasteride | Finasteride | 201 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 43 |
| Metformin Hcl Er | Metformin Hcl | 180 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 179 | 42 |
| Montelukast Sodium | Montelukast Sodium | 175 | 34 |
| Trulicity | Dulaglutide | 168 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 167 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 167 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 158 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 154 | 28 |
| Spironolactone | Spironolactone | 145 | 34 |
| Chlorthalidone | Chlorthalidone | 143 | 32 |
| Divalproex Sodium | Divalproex Sodium | 143 | 18 |
| Glipizide Er | Glipizide | 138 | 26 |
| Allopurinol | Allopurinol | 132 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 127 | 34 |
| Alendronate Sodium | Alendronate Sodium | 123 | 28 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 122 | 24 |
| Mirtazapine | Mirtazapine | 121 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 116 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 116 | 17 |
| Ozempic | Semaglutide | 115 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 111 | 26 |
| Aripiprazole | Aripiprazole | 108 | 14 |
| Donepezil Hcl | Donepezil Hcl | 102 | 19 |
| Olanzapine | Olanzapine | 100 | 15 |
| Risperidone | Risperidone | 100 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 99 | 24 |
| Famotidine | Famotidine | 93 | 21 |
| Buspirone Hcl | Buspirone Hcl | 90 | 18 |
| Lorazepam | Lorazepam | 89 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 25 |
| Mounjaro | Tirzepatide | 86 | 16 |
| Entresto | Sacubitril/Valsartan | 84 | suppressed |
| Simvastatin | Simvastatin | 84 | 17 |
| Xarelto | Rivaroxaban | 84 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 78 | 15 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 78 | suppressed |
| Levetiracetam | Levetiracetam | 76 | 14 |
| Pregabalin | Pregabalin | 73 | 21 |
| Ezetimibe | Ezetimibe | 72 | 14 |
| Sucralfate | Sucralfate | 72 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 69 | suppressed |
| Memantine Hcl | Memantine Hcl | 69 | suppressed |
| Bupropion Xl | Bupropion Hcl | 68 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 36 |
| Glipizide | Glipizide | 66 | 20 |
| Lamotrigine | Lamotrigine | 64 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 22 |
| Haloperidol | Haloperidol | 63 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 11 |
| Myrbetriq | Mirabegron | 61 | suppressed |
| Meloxicam | Meloxicam | 60 | 14 |
| Atenolol | Atenolol | 57 | 11 |
| Cephalexin | Cephalexin | 55 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 53 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 51 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 51 | 12 |
| Topiramate | Topiramate | 51 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 50 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 12 |
| Prednisone | Prednisone | 49 | 25 |
| Digoxin | Digoxin | 48 | suppressed |
| Latanoprost | Latanoprost | 47 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 47 | suppressed |
| Baclofen | Baclofen | 46 | 12 |
| Lovastatin | Lovastatin | 46 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Fluconazole | Fluconazole | 43 | 11 |
| Meclizine Hcl | Meclizine Hcl | 43 | suppressed |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Celecoxib | Celecoxib | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 41 | suppressed |
| Bumetanide | Bumetanide | 40 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 40 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 40 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 39 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 39 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Anastrozole | Anastrozole | 34 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 31 | suppressed |
| Amantadine | Amantadine Hcl | 30 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 30 | 30 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Humalog | Insulin Lispro | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 29 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Caplyta | Lumateperone Tosylate | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | 14 |
| Thiothixene | Thiothixene | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 18 |
| Atropine Sulfate | Atropine Sulfate | 26 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | 14 |
| Paliperidone Er | Paliperidone | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Daptomycin | Daptomycin | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 25 | suppressed |
| Ingrezza | Valbenazine Tosylate | 25 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 16 |
| Phenytek | Phenytoin Sodium Extended | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 13 |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Clozapine | Clozapine | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Nabumetone | Nabumetone | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 13 |
| Nystatin | Nystatin | 18 | 11 |
| Vraylar | Cariprazine Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 14 |
| Doxepin Hcl | Doxepin Hcl | 17 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Olanzapine Odt | Olanzapine | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 13 |
| Estradiol | Estradiol | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Movantik | Naloxegol Oxalate | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 16 | 11 |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 12 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Onglyza | Saxagliptin Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,240.60 · 67 records | PFIZER INC. | BEXSERO, BREZTRI, CAPLYTA, ELIQUIS, EVENITY, FANAPT, FREESTYLE LIBRE 2, FREESTYLE LIBRE 3, INGREZZA, Korlym, LEQVIO, MINIMED 780G, MOUNJARO, NEXPLANON, NURTEC ODT, OFEV, Ozempic, PAXLOVID, QULIPTA, REXULTI, REZDIFFRA, Rybelsus, SHINGRIX, SPRAVATO, Tymlos, UBRELVY, VYNDAQEL, Wegovy, ZAVZPRET, ZEPBOUND, Zunveyl | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Caplyta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error